371. A rapid method for determination of rosuvastatin in blood plasma with supported liquid extractionTjaša Dermota, Mojca Božič Mijovski, Jurij Trontelj, 2025, original scientific article Abstract: Introduction: Accurate measurement of rosuvastatin in plasma is critical for effective patient management and treatment monitoring following myocardial infarction (MI). Expensive solid-phase extraction (SPE) and timeconsuming liquid-liquid extraction (LLE) have been established for quantifying rosuvastatin. Supported liquid extraction (SLE) could offer a rapid, cost-effective alternative. Objectives: This study aimed to develop and validate a rapid, cost-effective, accurate, and precise method for quantifying rosuvastatin in high-dose plasma samples from patients following MI. Methods: Rosuvastatin was extracted from EDTA plasma using SLE and quantified with LC-MS/MS with positive electrospray ionization. The method was validated according to ICH M10 guidelines, focusing on selectivity, matrix effect, accuracy, precision, linearity, and carryover. Rosuvastatin-D6 was used as an internal standard. Additionally, thirty plasma samples from patients on high-dose rosuvastatin therapy (20 or 40 mg/day) following MI were analyzed by both LLE and SLE methods and compared. Results: The method was successfully validated, demonstrating linearity across a range of 0.1 ng/mL to 50 ng/mL. Compared to the LLE method, SLE achieved superior extraction recovery (96.3 % vs. 60 %) and precision (RSD: 11.9 % vs. 13.6 %) at 0.3 ng/mL rosuvastatin, with a lower absolute matrix effect (12.7 % vs.-36.7 %). Accuracy was comparable (109.3 % vs. 92.8 %). Although SLE involves higher initial costs, it significantly enhances throughput, reduces solvent usage, and minimizes contamination and equipment wear. Conclusion: This study validates SLE as a superior method for quantifying rosuvastatin in plasma, outperforming LLE in recovery, reproducibility, and automation. SLE offers greater accuracy and reliability, making it ideal for high-throughput applications.
Keywords: supported liquid extraction, liquid-liquid extraction, rosuvastatin, LC-MS/MS, myocardial infarction, solid-phase extraction, blood plasma
Published in DiRROS: 24.11.2025; Views: 165; Downloads: 62
 Full text (2,28 MB)
This document has many files! More... |
372. An evolutionarily conserved role for CTNNB1/ β-CATENIN in regulating the development of the corpus callosumArpan Parichha, Debarpita Datta, Amrita Singh, Ishita Talwar, Shreya Yadav, Špela Miroševič, Nina Žakelj, David Gosar, Damjan Osredkar, 2025, original scientific article Abstract: The corpus callosum (CC) is a major nerve bundle that connects the two hemispheres of the brain. Dysgenesis of the CC is associated with neurodevelopmental disorders such as the CTNNB1 syndrome. We identified that five individuals carrying CTNNB1 mutations displayed CC deficits. To explore CTNNB1/β-CATENIN-dependent mechanisms that regulate CC midline crossing, we examined mice with Ctnnb1 gain-of-function (GOF) or loss-of-function (LOF) selectively targeted to the early embryonic central nervous system midline using an Lmx1aCre driver. We identify that the Lmx1a lineage contributes to midline cell populations known to regulate CC pathfinding: the glial wedge, the indusium griseum glia, and a population of midline glutamatergic neurons. We find that each of these structures are affected in both GOF and LOF embryos, resulting in a profound disruption of CC crossing and formation of Probst bundles. Thus, regulated β-CATENIN function in midline cell populations is critical for CC development and its dysregulation may underlie the CC deficits associated with CTNNB1 syndrome.
Keywords: neurodevelopment, molecular neuroscience, CTNNB1 syndrome, corpus callosum development
Published in DiRROS: 24.11.2025; Views: 165; Downloads: 76
Full text (27,02 MB)
This document has many files! More... |
373. |
374. |
375. |
376. |
377. |
378. |
379. |
380. |
